Literature DB >> 675855

An improved criterion for the evaluation of estrogen receptor binding data in human breast cancer.

G di Fronzo, A Bertuzzi, E Ronchi.   

Abstract

The evaluation of the data is an important step in performing the estrogen receptor test. For this reason an effort has been made to derive a more reliable threshold criteria. Among the parameters considered, Xo, Ka, and BI%, only the former 2 appear to be suitable to allow a proper evaluation of the results. From the analysis of different types of carcinomatous or normal breast specimens, limit values of these parameters have been recovered for positivity and negativity of the estrogen receptor test. We found all the samples showing Ka less than 1.5 x 10(9) M-1 or Xo less than 5 fmol/mg proteins to be negative, those characterized by low values of both the parameters were borderline, and all the remaining ones were positive.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 675855     DOI: 10.1177/030089167806400303

Source DB:  PubMed          Journal:  Tumori        ISSN: 0300-8916


  4 in total

1.  Adjuvant chemotherapy in postmenopausal women: results of sequential noncross-resistant regimens.

Authors:  C Brambilla; A Rossi; P Valagussa; G Bonadonna
Journal:  World J Surg       Date:  1985-10       Impact factor: 3.352

2.  Bilateral ovariectomy in premenopausal patients with advanced breast cancer, after the evaluation of estrogen receptors and urinary androgen excretion.

Authors:  S Oriana; G Secreto; A Severini; G Di Fronzo; M Di Giuseppe; P Valagussa; F Preda
Journal:  Breast Cancer Res Treat       Date:  1982       Impact factor: 4.872

3.  Estrogen-receptor status and response to chemotherapy in early and advanced breast cancer.

Authors:  G Bonadonna; P Valagussa; G Tancini; G Di Fronzo
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

4.  Relationship among estrogen receptors, proliferative activity and menopausal status in breast cancer.

Authors:  A Bertuzzi; M G Daidone; G Di Fronzo; R Silvestrini
Journal:  Breast Cancer Res Treat       Date:  1981       Impact factor: 4.872

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.